S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NASDAQ:MTEM

Molecular Templates (MTEM) Stock Price, News & Analysis

$2.24
-0.12 (-5.08%)
(As of 03/28/2024 ET)
Today's Range
$2.10
$2.78
50-Day Range
$1.75
$4.03
52-Week Range
$1.68
$9.45
Volume
377,259 shs
Average Volume
32,316 shs
Market Capitalization
$12.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Molecular Templates MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.62% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
0.96mentions of Molecular Templates in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.15) to ($2.70) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.27 out of 5 stars

Medical Sector

363rd out of 938 stocks

Pharmaceutical Preparations Industry

164th out of 417 stocks

MTEM stock logo

About Molecular Templates Stock (NASDAQ:MTEM)

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company primarily develops therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

MTEM Stock Price History

MTEM Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Molecular Templates, Inc. Provides Interim Update
Molecular Templates, Inc. Provides Interim Update
Molecular Templates Inc MTEM
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
After layoffs, Molecular Templates overhauls C-suite
Molecular Templates launches $40M private placement
See More Headlines
Receive MTEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Molecular Templates and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
3/28/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MTEM
CUSIP
88580720
Employees
111
Year Founded
2009

Profitability

Net Income
$-92,720,000.00
Pretax Margin
-49.52%

Debt

Sales & Book Value

Annual Sales
$19.75 million
Book Value
($4.03) per share

Miscellaneous

Free Float
4,369,000
Market Cap
$12.03 million
Optionable
No Data
Beta
1.20

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

MTEM Stock Analysis - Frequently Asked Questions

How have MTEM shares performed in 2024?

Molecular Templates' stock was trading at $3.73 at the beginning of 2024. Since then, MTEM stock has decreased by 39.9% and is now trading at $2.24.
View the best growth stocks for 2024 here
.

Are investors shorting Molecular Templates?

Molecular Templates saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 27,300 shares, a decline of 29.8% from the February 29th total of 38,900 shares. Based on an average trading volume of 15,300 shares, the short-interest ratio is presently 1.8 days. Approximately 0.6% of the shares of the stock are sold short.
View Molecular Templates' Short Interest
.

When is Molecular Templates' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our MTEM earnings forecast
.

How were Molecular Templates' earnings last quarter?

Molecular Templates, Inc. (NASDAQ:MTEM) announced its quarterly earnings results on Monday, November, 15th. The biotechnology company reported ($8.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.67) by $2.43. The biotechnology company earned $2.38 million during the quarter, compared to analyst estimates of $15.69 million.

When did Molecular Templates' stock split?

Molecular Templates shares reverse split on the morning of Monday, August 14th 2023. The 1-15 reverse split was announced on Friday, August 11th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Molecular Templates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP), Novavax (NVAX), Gilead Sciences (GILD), TG Therapeutics (TGTX), Pfizer (PFE), Synergy Pharmaceuticals (SGYP), Amarin (AMRN), Corbus Pharmaceuticals (CRBP) and Exelixis (EXEL).

Who are Molecular Templates' major shareholders?

Molecular Templates' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.34%), Vanguard Group Inc. (2.34%), Monashee Investment Management LLC (2.27%), Virtu Financial LLC (0.19%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Jason S Kim, Kevin M Lalande, Sean Mclennan, Shv Management Services, Llc and Target N V Biotech.
View institutional ownership trends
.

How do I buy shares of Molecular Templates?

Shares of MTEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MTEM) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners